PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1577591
PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1577591
Marine Pharmaceuticals
Global Marine Pharmaceuticals Market to Reach US$6.9 Billion by 2030
The global market for Marine Pharmaceuticals estimated at US$4.1 Billion in the year 2023, is expected to reach US$6.9 Billion by 2030, growing at a CAGR of 7.6% over the analysis period 2023-2030. Oncology End-Use, one of the segments analyzed in the report, is expected to record a 8.1% CAGR and reach US$3.3 Billion by the end of the analysis period. Growth in the Cardiovascular End-Use segment is estimated at 7.5% CAGR over the analysis period.
The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 7.3% CAGR
The Marine Pharmaceuticals market in the U.S. is estimated at US$1.1 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 7.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.0% and 6.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.0% CAGR.
Global Marine Pharmaceuticals Market - Key Trends & Drivers Summarized
What Are Marine Pharmaceuticals, and Why Are They Important in Modern Medicine?
Marine pharmaceuticals refer to drugs and therapeutic compounds derived from marine organisms such as algae, sponges, mollusks, and bacteria. These compounds have unique chemical structures and biological activities that make them valuable for treating a wide range of diseases, including cancer, inflammation, and infectious diseases. Marine environments, particularly extreme habitats like deep-sea vents and coral reefs, have become a treasure trove of bioactive substances that offer potential as novel drug candidates. Researchers and pharmaceutical companies are increasingly exploring the ocean's biodiversity for new, more effective treatments, leveraging the natural compounds found in marine organisms to develop drugs with unique mechanisms of action. Some notable examples include marine-derived drugs like ziconotide, used for chronic pain management, and trabectedin, an anti-cancer agent. The potential for discovering novel drugs from marine resources has positioned marine pharmaceuticals as a promising and rapidly evolving field within the biotechnology and pharmaceutical industries.
How Are Technological Advancements Expanding Opportunities in Marine Drug Discovery?
Technological advancements have significantly expanded the possibilities for discovering and developing marine pharmaceuticals. Modern techniques like genomics, proteomics, and metabolomics allow scientists to explore marine biodiversity at a molecular level, identifying and isolating bioactive compounds more efficiently. The development of deep-sea exploration technology and remote-operated vehicles (ROVs) has also enabled researchers to access previously unreachable marine environments, increasing the potential for finding new organisms with unique biochemical properties. Furthermore, advancements in high-throughput screening and bioprospecting have accelerated the identification of drug candidates from marine organisms. Innovations in synthetic biology and bioengineering are also helping pharmaceutical companies recreate marine compounds in the laboratory, ensuring sustainable production without depleting natural marine resources. These technological breakthroughs are driving progress in marine drug development, opening the door to new treatments for diseases that are resistant to traditional therapies.
Why Are Sustainability and Regulation Crucial to the Growth of Marine Pharmaceuticals?
The exploration of marine environments for pharmaceutical development raises important sustainability and regulatory considerations. Harvesting marine organisms for drug development can have significant ecological impacts, particularly in fragile ecosystems such as coral reefs or deep-sea environments. As a result, there is increasing pressure on pharmaceutical companies and researchers to adopt sustainable practices, such as sourcing marine compounds through aquaculture, synthetic production, or microbial fermentation. Additionally, the regulation of marine bioprospecting is evolving, with countries enforcing stricter controls on the extraction of marine resources within their territorial waters. International agreements like the Nagoya Protocol, which governs access to genetic resources, are playing a key role in shaping the policies around marine pharmaceutical exploration. Companies must navigate these regulatory frameworks to ensure the ethical and legal acquisition of marine compounds while minimizing their environmental footprint.
What Is Driving the Growth of the Global Marine Pharmaceuticals Market?
The growth in the global marine pharmaceuticals market is driven by several factors, including advances in marine biotechnology, increased research funding, and the rising demand for novel drugs to combat diseases. One key growth driver is the growing recognition of the ocean as an untapped source of biologically active compounds, particularly in the search for new antibiotics and anti-cancer agents. Technological advancements in drug discovery, such as high-throughput screening and bioinformatics, are making it easier to identify potential drug candidates from marine organisms. The increasing prevalence of drug-resistant diseases and the need for alternative therapies are also fueling interest in marine-derived pharmaceuticals. Furthermore, the expansion of collaborative efforts between academic institutions, research organizations, and pharmaceutical companies is accelerating innovation in the field. Governments and private entities are increasing investments in marine drug discovery programs, further driving market growth. As awareness of marine biodiversity’s potential grows, the marine pharmaceuticals market is poised for continued expansion.
Select Competitors (Total 43 Featured) -
- AbbVie, Inc.
- Aphios Corporation
- BioMarin Pharmaceutical
- Cyanotech Corporation
- GlycoMar Ltd.
- GSK Plc
- MARINE LIFESCIENCES
- Marine Polymer Technologies, Inc.
- Marinomed Biotech AG
- Pelagia AS
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Impact of Covid-19 and a Looming Global Recession
- Marine Pharmaceuticals - Global Key Competitors Percentage Market Share in 2024 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- Increasing Focus on Drug Discovery from Marine Sources Throws Spotlight on the Growing Potential of Marine Pharmaceuticals
- Rising Prevalence of Drug-Resistant Diseases Spurs Significant Growth in Research for Marine-Derived Antibiotics
- Technological Advancements in Marine Biotechnology Strengthens the Business Case for Exploring Novel Marine Bioactive Compounds
- Expansion of Marine Bioprospecting Expands Addressable Market Opportunity for Marine-Based Drug Development
- Rising Demand for Alternative Cancer Treatments Drives Adoption of Marine-Derived Anticancer Compounds
- Growing Awareness of Sustainability and Eco-Friendly Sourcing Generates Demand for Sustainable Harvesting of Marine Pharmaceuticals
- Increasing Use of Marine-Derived Compounds in Chronic Disease Management Propels Growth in Marine Pharmaceuticals
- Integration of Genomics and Bioinformatics in Marine Drug Discovery Strengthens the Case for More Targeted Drug Development
- Rising Investment in Marine Biotechnology Research Generates Opportunities for New Therapeutic Agents from Marine Organisms
- Increased Focus on Marine Ecosystem Conservation Expands the Need for Sustainable Marine Pharmaceutical Practices
- Growing Demand for Natural and Biocompatible Therapies Propels Market Growth for Marine-Derived Nutraceuticals and Pharmaceuticals
- Advancements in Extraction and Cultivation Techniques Drive Adoption of Marine Pharmaceuticals by Reducing Production Costs
- Rising Incidence of Neurological Disorders Expands Research into Marine-Derived Neuroprotective Agents
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Marine Pharmaceuticals Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
- TABLE 2: World Recent Past, Current & Future Analysis for Marine Pharmaceuticals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 3: World Historic Review for Marine Pharmaceuticals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 4: World 16-Year Perspective for Marine Pharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
- TABLE 5: World Recent Past, Current & Future Analysis for Oncology End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 6: World Historic Review for Oncology End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 7: World 16-Year Perspective for Oncology End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- TABLE 8: World Recent Past, Current & Future Analysis for Cardiovascular End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 9: World Historic Review for Cardiovascular End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 10: World 16-Year Perspective for Cardiovascular End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- TABLE 11: World Recent Past, Current & Future Analysis for Infectious Diseases End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 12: World Historic Review for Infectious Diseases End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 13: World 16-Year Perspective for Infectious Diseases End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
- TABLE 14: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 15: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 16: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
- UNITED STATES
- Marine Pharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
- TABLE 17: USA Recent Past, Current & Future Analysis for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 18: USA Historic Review for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 19: USA 16-Year Perspective for Marine Pharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses for the Years 2014, 2024 & 2030
- CANADA
- TABLE 20: Canada Recent Past, Current & Future Analysis for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 21: Canada Historic Review for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 22: Canada 16-Year Perspective for Marine Pharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses for the Years 2014, 2024 & 2030
- JAPAN
- Marine Pharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
- TABLE 23: Japan Recent Past, Current & Future Analysis for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 24: Japan Historic Review for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 25: Japan 16-Year Perspective for Marine Pharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses for the Years 2014, 2024 & 2030
- CHINA
- Marine Pharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
- TABLE 26: China Recent Past, Current & Future Analysis for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 27: China Historic Review for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 28: China 16-Year Perspective for Marine Pharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses for the Years 2014, 2024 & 2030
- EUROPE
- Marine Pharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
- TABLE 29: Europe Recent Past, Current & Future Analysis for Marine Pharmaceuticals by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
- TABLE 30: Europe Historic Review for Marine Pharmaceuticals by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 31: Europe 16-Year Perspective for Marine Pharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
- TABLE 32: Europe Recent Past, Current & Future Analysis for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 33: Europe Historic Review for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 34: Europe 16-Year Perspective for Marine Pharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses for the Years 2014, 2024 & 2030
- FRANCE
- Marine Pharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
- TABLE 35: France Recent Past, Current & Future Analysis for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 36: France Historic Review for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 37: France 16-Year Perspective for Marine Pharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses for the Years 2014, 2024 & 2030
- GERMANY
- Marine Pharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
- TABLE 38: Germany Recent Past, Current & Future Analysis for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 39: Germany Historic Review for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 40: Germany 16-Year Perspective for Marine Pharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses for the Years 2014, 2024 & 2030
- ITALY
- TABLE 41: Italy Recent Past, Current & Future Analysis for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 42: Italy Historic Review for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 43: Italy 16-Year Perspective for Marine Pharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses for the Years 2014, 2024 & 2030
- UNITED KINGDOM
- Marine Pharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
- TABLE 44: UK Recent Past, Current & Future Analysis for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 45: UK Historic Review for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 46: UK 16-Year Perspective for Marine Pharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses for the Years 2014, 2024 & 2030
- REST OF EUROPE
- TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 48: Rest of Europe Historic Review for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 49: Rest of Europe 16-Year Perspective for Marine Pharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses for the Years 2014, 2024 & 2030
- ASIA-PACIFIC
- Marine Pharmaceuticals Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
- TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 51: Asia-Pacific Historic Review for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 52: Asia-Pacific 16-Year Perspective for Marine Pharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses for the Years 2014, 2024 & 2030
- REST OF WORLD
- TABLE 53: Rest of World Recent Past, Current & Future Analysis for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
- TABLE 54: Rest of World Historic Review for Marine Pharmaceuticals by End-Use - Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
- TABLE 55: Rest of World 16-Year Perspective for Marine Pharmaceuticals by End-Use - Percentage Breakdown of Value Sales for Oncology End-Use, Cardiovascular End-Use, Infectious Diseases End-Use and Other End-Uses for the Years 2014, 2024 & 2030
IV. COMPETITION
